Epigenetics and Colorectal Cancer

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2011 Oct 20

PMID 22009203

Citations 365

Authors

Victoria Valinluck Lao

William M Grady

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. It results from an accumulation of genetic and epigenetic changes in colon epithelial cells, which transforms them into adenocarcinomas. Over the past decade, major advances have been made in understanding cancer epigenetics, particularly regarding aberrant DNA methylation. Assessment of the colon cancer epigenome has revealed that virtually all CRCs have aberrantly methylated genes and that the average CRC methylome has hundreds to thousands of abnormally methylated genes. As with gene mutations in the cancer genome, a subset of these methylated genes, called driver genes, is presumed to have a functional role in CRC. The assessment of methylated genes in CRCs has also revealed a unique molecular subgroup of CRCs called CpG island methylator phenotype (CIMP) cancers; these tumors have a particularly high frequency of methylated genes. These advances in our understanding of aberrant methylation in CRC have led to epigenetic alterations being developed as clinical biomarkers for diagnostic, prognostic and therapeutic applications. Progress in this field suggests that these epigenetic alterations will be commonly used in the near future to direct the prevention and treatment of CRC.

Citing Articles

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.

Singer M, Valerin J, Zhang Z, Zhang Z, Dayyani F, Yaghmai V Cells. 2025; 14(3).

PMID: 39936958 PMC: 11817869. DOI: 10.3390/cells14030166.

Changes in Lysine Methylation Contribute to the Cytotoxicity of Curcumin in Colon Cancer Cells.

Santarelli R, Curra P, Di Crosta M, Gonnella R, Gilardini Montani M, Cirone M Molecules. 2025; 30(2.

PMID: 39860204 PMC: 11767838. DOI: 10.3390/molecules30020335.

Advances in Molecular Mechanisms and Therapeutic Strategies in Colorectal Cancer: A New Era of Precision Medicine.

Delle Cave D Int J Mol Sci. 2025; 26(1.

PMID: 39796202 PMC: 11719900. DOI: 10.3390/ijms26010346.

DNA methylation-driven gene FAM3D promotes colorectal cancer growth via the ATF4-SESN2-mTORC1 pathway.

Zheng T, Zhang D, Fu Q, Wang M, Cheng Z, Cao Y Aging (Albany NY). 2024; 16(19):12866-12892.

PMID: 39388305 PMC: 11501385. DOI: 10.18632/aging.206115.

DNA demethylation triggers cell free DNA release in colorectal cancer cells.

Pessei V, Macagno M, Mariella E, Congiusta N, Battaglieri V, Battuello P Genome Med. 2024; 16(1):118.

PMID: 39385243 PMC: 11462661. DOI: 10.1186/s13073-024-01386-5.

References

Sawan C, Herceg Z . Histone modifications and cancer. Adv Genet. 2010; 70:57-85. DOI: 10.1016/B978-0-12-380866-0.60003-4. View

Limsui D, Vierkant R, Tillmans L, Wang A, Weisenberger D, Laird P . Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010; 102(14):1012-22. PMC: 2915616. DOI: 10.1093/jnci/djq201. View

Pritchard C, Grady W . Colorectal cancer molecular biology moves into clinical practice. Gut. 2010; 60(1):116-29. PMC: 3006043. DOI: 10.1136/gut.2009.206250. View

Baylin S, Bestor T . Altered methylation patterns in cancer cell genomes: cause or consequence?. Cancer Cell. 2002; 1(4):299-305. DOI: 10.1016/s1535-6108(02)00061-2. View

Issa J, Vertino P, Wu J, Sazawal S, Celano P, Nelkin B . Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst. 1993; 85(15):1235-40. DOI: 10.1093/jnci/85.15.1235. View

Oster B, Thorsen K, Lamy P, Wojdacz T, Hansen L, Birkenkamp-Demtroder K . Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer. 2011; 129(12):2855-66. DOI: 10.1002/ijc.25951. View

Rashid A, Shen L, Morris J, Issa J, Hamilton S . CpG island methylation in colorectal adenomas. Am J Pathol. 2001; 159(3):1129-35. PMC: 1850474. DOI: 10.1016/S0002-9440(10)61789-0. View

Konishi K, Shen L, Jelinek J, Watanabe Y, Ahmed S, Kaneko K . Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila). 2009; 2(9):814-22. PMC: 3544187. DOI: 10.1158/1940-6207.CAPR-09-0054. View

Sakatani T, Kaneda A, Iacobuzio-Donahue C, Carter M, de Boom Witzel S, Okano H . Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science. 2005; 307(5717):1976-8. DOI: 10.1126/science.1108080. View

10.

Saito Y, Jones P . Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle. 2006; 5(19):2220-2. DOI: 10.4161/cc.5.19.3340. View

11.

Grady W, Parkin R, Mitchell P, Lee J, Kim Y, Tsuchiya K . Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene. 2008; 27(27):3880-8. DOI: 10.1038/onc.2008.10. View

12.

McCabe M, Lee E, Vertino P . A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation. Cancer Res. 2009; 69(1):282-91. PMC: 2653261. DOI: 10.1158/0008-5472.CAN-08-3274. View

13.

Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh C, Feinberg A . Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002; 62(22):6442-6. View

14.

Valinluck V, Sowers L . Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res. 2007; 67(12):5583-6. DOI: 10.1158/0008-5472.CAN-07-0846. View

15.

Shannon B, Gnanasampanthan S, Beilby J, Iacopetta B . A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut. 2002; 50(4):520-4. PMC: 1773174. DOI: 10.1136/gut.50.4.520. View

16.

Ide T, Kitajima Y, Ohtaka K, Mitsuno M, Nakafusa Y, Miyazaki K . Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer. Oncol Rep. 2008; 19(6):1571-6. View

17.

Hinoue T, Weisenberger D, Pan F, Campan M, Kim M, Young J . Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One. 2009; 4(12):e8357. PMC: 2791229. DOI: 10.1371/journal.pone.0008357. View

18.

Itzkowitz S, Jandorf L, Brand R, Rabeneck L, Schroy 3rd P, Sontag S . Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2006; 5(1):111-7. DOI: 10.1016/j.cgh.2006.10.006. View

19.

Issa J, Ottaviano Y, Celano P, Hamilton S, Davidson N, Baylin S . Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994; 7(4):536-40. DOI: 10.1038/ng0894-536. View

20.

Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J . Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995; 268(5215):1336-8. DOI: 10.1126/science.7761852. View